MTPConnect is delivering a new $28.5 million investment for TTRA Drugs and Devices for the MRFF, injecting much-needed funding and support for Australian small to medium enterprises (SMEs), and which builds on the legacy of the inaugural research accelerator program.
The objective of TTRA Drugs and Devices is to accelerate development and commercialisation of promising drugs and medical devices into products that can reduce the burden of cardiovascular disease and complications of diabetes for patients, carers, families, and community.
TTRA Drugs and Devices is delivered in collaboration with Impact Partners CSL and Roche Diagnostics Australia who bring additional industry knowledge, market expertise and commercialisation experience.
TTRA Devices Round 2 Funding Call Now Closed
FUNDING GUIDELINES VIEW TTRA DEVICES INFORMATION SESSION WEBINAR
A new TTRA Devices Round 2 investment opportunity was opened in February 2026, providing up to $1 million to help eligible Australian start-ups, spin-outs and SMEs develop innovative preventative, diagnostic, therapeutic and/or disease management devices for cardiovascular disease and the complications of diabetes (type 1 and type 2).
Expressions of Interest for this opportunity closed on 30 March 2026. Applications are currently being reviewed as part of a multi-step process, and outcomes will be communicated in August/September 2026.
For queries, please contact the TTRA team via email.
TTRA Drugs and Devices Round 1
In June 2025, MTPConnect announced the injection of $12.07 million to back 14 homegrown life science companies developing new medical devices and drugs for heart disease and diabetes. The news was announced by the Minister for Health and Ageing The Hon Mark Butler.
TTRA Drugs Investment Outcomes (in alphabetical order)
- Anaxis Pharma Pty Ltd, Victoria, $333,236 Tranche A investment
Breaking the cycle: targeting cell death in diabetic kidney disease
- Argenica Therapeutics Limited, Western Australia, $1,000,000 Tranche A investment
Phase 2b/3 adaptive trial to determine the safety and efficacy of ARG-007 in reducing disability in acute ischaemic stroke patients
- Aspecthera Pty Ltd, Tasmania, $500,000 Tranche A investment
Novel eye-drop therapy for mild, moderate and severe non-proliferative diabetic retinopathy to prevent vision loss and disease progression
- Atherid Therapeutics Pty Ltd, Western Australia, $750,000 Tranche A investment
Establishing GMP production of a biologic therapeutic for treating patients with atherosclerotic cardiovascular disease
- Endo Axiom Pty Ltd, New South Wales, $1,079,424 Tranche A investment
Beyond the needle: Evaluating a safe and smart oral insulin in type 1 diabetes
- Inosi Therapeutics Pty Ltd, Victoria, $968,192.63 Tranche A investment
Development of an IRAP inhibitor for the treatment of diabetic kidney disease
- Nanomedx Pty Ltd, New South Wales, $750,000 Tranche A investment
Local regulation of inflammation for the treatment of peripheral arterial disease
- ProGenis Pharmaceuticals Pty Ltd, Western Australia, $369,706 Tranche A investment
PGP-011 as an effective RNA therapeutic for improving insulin sensitivity
TTRA Devices Investment Outcomes (in alphabetical order)
- CathRx Ltd, New South Wales, $1,100,000 Tranche A investment
ElectroPulse pulsed field ablation system to treat AF (ELECTROPULSE AF)
- I D & E Pty Ltd, New South Wales, $1,200,000 Tranche A investment
Ocular drug delivery system
- Theia Medical Pty Ltd, South Australia, $1,000,000 Tranche A investment
Hybrid 3D-printed intravascular imaging device for accurate detection of high-risk coronary artery disease
- ZiP Diagnostics Pty Ltd, Victoria, $1,019,134 Tranche A investment
Development of a low-cost, rapid, point-of-care lateral flow test for prediction and early diagnosis of preeclampsia
Resources
News
TTRA Information Session Webinar – Funding call for Devices addressing cardiovascular disease and complications of diabetes
In this webinar, find out more about the TTRA Devices Round 2 investment opportunity, providing up to $1 million to help eligible Australian start-ups, spin-outs and SMEs develop innovative preventative, diagnostic, therapeutic and/or disease management devices for cardiovascular disease and the complications of diabetes (type 1 and type 2).
Read MoreNews
MTPConnect Opens New Funding Round for Medtech Innovators in Heart Disease and Diabetes
MTPConnect has opened expressions of interest for a new funding round for medical devices under its TTRA initiative.
Read MoreNews
TTRA Drugs and Devices Cohort Come Together for Commercialisation Intensive
Bringing together 12 breakthrough companies as part of MTPConnect’s Targeted Translation Research Accelerator (TTRA) Drugs & Devices cohort in Sydney
Read MoreNews
